Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 6/20 | 0.61 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804952 | 0.79 | IMPDH2 (0.66) | IMPDH2KDM4ELMNACYP1A2CYP3A4 | |
| SCHEMBL6832863 | 0.76 | IMPDH2 (0.61) | IMPDH2AXLKDM4ELMNACYP1A2 | |
| SCHEMBL2162254 | 0.76 | IMPDH2 (1.00) | IMPDH2AXLKDM4ELMNACYP1A2 | |
| SCHEMBL1705034 | 0.76 | IMPDH2 (0.61) | IMPDH2KDM4ELMNACYP1A2CYP3A4 | |
| SCHEMBL25268695 | 0.76 | IMPDH2 (0.52) | IMPDH2AXLKDM4ELMNACYP1A2 | |
| SCHEMBL25217587 | 0.76 | IMPDH2 (0.52) | IMPDH2AXLKDM4ELMNACYP1A2 | |
| SCHEMBL19641735 | 0.76 | IMPDH2 (0.52) | IMPDH2AXLKDM4ELMNACYP1A2 | |
| SCHEMBL15047872 | 0.76 | IMPDH2 (0.61) | IMPDH2AXLKDM4ELMNACYP1A2 | |
| SCHEMBL1706043 | 0.76 | IMPDH2 (0.61) | IMPDH2KDM4ELMNACYP1A2CYP3A4 | |
| SCHEMBL31552249 | 0.76 | IMPDH2 (0.61) | IMPDH2KDM4ELMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692057-A1 | NOVEL B0AT1 INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| CN-118843626-A | Heterocyclic compounds as DYRK1A inhibitors | 普罗塞纳生物科学有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024210198-A1 | NOVEL B0AT1 INHIBITOR | 田辺三菱製薬株式会社 | 2024-10-10 | — | — | WO | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| US-11466016-B2 | Pharmaceutical compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3759111-A1 | PHARMACEUTICAL COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-01-06 | — | — | EP | disclosed |
| CN-111902415-A | Pharmaceutical compounds | 大冢制药株式会社 | 2020-11-06 | — | — | CN | disclosed |
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| EP-2351748-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-2351748-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | IMPDH2 4164/4885AXL 969/4885KDM4E 874/4885 |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | BCAT1, BCAT2, BHMT | IMPDH2 558/4885AXL 3965/4885KDM4E 3501/4885 |
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | MAPT, CYP3A5, SLC5A1 | IMPDH2 1274/4885AXL 2401/4885KDM4E 2767/4885 |
| US-11466016-B2 | Pharmaceutical compounds | MAPT, CYP3A5, SLC5A1 | IMPDH2 1274/4885AXL 2401/4885KDM4E 2767/4885 |
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE5A, PDE2A, PDE3A | IMPDH2 38/4885AXL 4306/4885KDM4E 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.